Employees: 2,084
Size Henan Taloph Pharmaceutical Stock (600222.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $497M, the 3714th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.12 on 18 Nov 2026.
Performance Over six months the shares fell 21.1%, against -18.4% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 4.7% over the last twelve months (peer median +9.8%); the operating margin is 6.8% (peer median 10.0%).
Valuation It trades at 2.5× enterprise value to sales against a peer median of 4.0× (7th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.7 points below its cost of capital (7.4% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.70B | CN¥1.75B | CN¥1.94B | CN¥2.06B | CN¥1.96B |
| Revenue growth | — | -10% | -6% | +6% | — |
| Gross profit | CN¥495M | CN¥453M | CN¥461M | CN¥534M | CN¥444M |
| EBITDA | n/a | CN¥199M | CN¥147M | CN¥160M | CN¥59.5M |
| Net income | CN¥50.9M | CN¥60.0M | CN¥50.5M | CN¥43.6M | -CN¥72.2M |
| Free cash flow | CN¥46.0M | CN¥64.8M | -CN¥74.2M | CN¥55.7M | -CN¥132M |
| Capital expenditure | CN¥16.7M | CN¥21.1M | CN¥37.2M | CN¥43.1M | CN¥66.6M |
| Total debt | CN¥1.24B | CN¥1.31B | CN¥1.09B | CN¥819M | CN¥775M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600222.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.7% | -2.1% | 4th lowest of 21 |
| 6-month return | -21.1% | -18.4% | 9th lowest of 21 |
| Distance from 52-week high | -35.2% | -37.4% | 10th highest of 21 |
| Revenue growth (TTM) | -4.7% | +9.8% | 5th lowest of 20 |
| Operating margin | 6.8% | 10.0% | 10th lowest of 20 |
| EV / Sales | 2.5× | 4.0× | 7th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 16.7% | -0.7% | 2nd most demanding of 9 |
| Growth delivered (Del g) | +4.4% | +7.0% | 4th lowest of 9 |
| Hurdle (Req g minus delivered) | +12.3 pp | -6.6 pp | 2nd most demanding of 9 |
| ROIC minus cost of capital | -2.7 pp | -2.4 pp | 9th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | 2.5× | 16.7% | +4.4% |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | 11.0× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | 1.8× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | 4.0× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | 5.6× | n/a | n/a |